Reproductive Medicine Center, Xiamen University Affiliated Chenggong Hospital, Xiamen, Fujian, China.
Medical College, Xiamen University, Xiamen, Fujian, China.
Front Endocrinol (Lausanne). 2024 May 22;15:1380778. doi: 10.3389/fendo.2024.1380778. eCollection 2024.
To investigate the interaction between atosiban and growth hormone (GH) as adjuvants in frozen-thawed embryo transfer (FET) cycles.
A total of 11627 patients who underwent FET at Xiamen University Affiliated Chenggong Hospital between January 2018 to December 2022 were retrospectively analyzed. Among them, 482 patients received atosiban and 275 patients received GH. The interactions were estimated by comparing the odds ratio (OR) for pregnancy comparing patients with or without atosiban adjuvant in cohorts stratified according to the presence of GH use in either the overall cohort or a propensity score (PS) matched cohort. An interaction term (atosiban × GH) was introduced to a multivariate model to calculate the ratio of OR (ORR) adjusted for confounders.
For all patients receiving atosiban administration, no obvious effect on pregnancy was observed in comparison with either matched or unmatched controls. However, when the patients were stratified according to GH administration, atosiban showed a significant association with clinical pregnancy in comparison with either matched or unmatched controls among patients with GH treatment with rate ratios (RR) of 1.32 (95%CI: 1.05,1.67) and 1.35 (95%CI: 1,1.82), respectively. On the other hand, however, the association was absent among patients without GH treatment. The adjusted ORRs in both matched and unmatched cohorts were 2.44 (95%CI: 1.07,5.84) and 1.95 (95%CI: 1.05, 3.49) respectively.
The combination use of atosiban and GH in FET cycles is potentially beneficial to the pregnancy. However, indications for the use of atosiban and GH may need further assessment.
研究阿托西班与生长激素（GH）在冻融胚胎移植（FET）周期中的协同作用。
回顾性分析 2018 年 1 月至 2022 年 12 月在厦门大学附属成功医院接受 FET 的 11627 例患者。其中，阿托西班组 482 例，GH 组 275 例。通过比较在整个队列或倾向评分（PS）匹配队列中根据 GH 使用情况分层的队列中，有或没有阿托西班辅助治疗的患者妊娠的比值比（OR），评估相互作用。在多变量模型中引入相互作用项（阿托西班×GH），以计算调整混杂因素后的 OR 比（ORR）。
在接受阿托西班治疗的所有患者中，与匹配或未匹配的对照组相比，妊娠率未见明显差异。然而，当根据 GH 治疗情况对患者进行分层时，与匹配或未匹配的对照组相比，在接受 GH 治疗的患者中，阿托西班与临床妊娠显著相关，RR 分别为 1.32（95%CI：1.05，1.67）和 1.35（95%CI：1，1.82）。另一方面，在未接受 GH 治疗的患者中，这种关联并不存在。在匹配和未匹配的队列中，调整后的 ORR 分别为 2.44（95%CI：1.07，5.84）和 1.95（95%CI：1.05，3.49）。
在 FET 周期中联合使用阿托西班和 GH 可能对妊娠有益。然而，阿托西班和 GH 的使用指征可能需要进一步评估。
